Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Prostatic Artery Embolization for Improving Lower Urinary Tract Symptoms in Patients with Prostate Cancer Undergoing Radiation Therapy

Trial Status: active

This phase I trial evaluates whether prostatic artery embolization (PAE) can improve lower urinary tract symptoms in patients undergoing radiation therapy for prostate cancer. Patients with prostate cancer may experience lower urinary tract symptoms (LUTS), which can significantly decrease their quality of life. They may choose to undergo transurethral prostatic resection surgery for relief, but the procedure is associated with many complications. Additionally, as patients age and have associated medical comorbidities (two or more diseases at the same time), they may not be candidates for surgery. PAE uses Embosphere microspheres, tiny particles about the size of a grain of sand made of a type of gelatin, injected into a blood vessel close to the tumor to block blood flow to the tumor and reduce its size. PAE provides a minimally invasive treatment option that may effectively reduce lower urinary tract symptoms in prostate cancer patients with a low risk of side-effects. The procedure can often be performed in patients that do not qualify for surgery or otherwise prefer to avoid surgery. PAE may improve LUTS and decrease the prostate size in patients with prostate cancer undergoing radiation therapy.